Thyroid Gland Papillary Carcinoma — Research

Thyroid Gland Papillary Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	8,928	`("Thyroid Cancer, Papillary"[mh] OR "Cancer, Papillary Thyroid"[mh] OR "Carcinoma, Papillary Thyroid"[mh])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	3,993	`("Thyroid Cancer, Papillary"[mh] OR "Cancer, Papillary Thyroid"[mh] OR "Carcinoma, Papillary Thyroid"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	649	`("Thyroid Cancer, Papillary"[mh] OR "Cancer, Papillary Thyroid"[mh] OR "Carcinoma, Papillary Thyroid"[mh]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 17 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (17)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–17 of 17 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.